TrialDoklady. Biochemistry and biophysics2024

Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic.

A A Akimova et al.PubMed ↗Publisher ↗

No numbers read from the abstract.